At a glance
R&D supply markets
China share of India API imports
74%
FY25
OfficialMinistry of Chemicals and Fertilizers (reply to Parliament, Mar 2026) · Sep 2026
Thermo Fisher organic
+6%
Lab demand recovering
OfficialThermo Fisher Q3 2026 results and call · Oct 2026
R&D supply markets have turned in suppliers' favour: CRO bookings and CDMO growth are strong, and US tariffs and BIOSECURE are reshaping where things are made. Lab supplies and APIs are the exceptions, with soft prices to lock in now.
Subcategories
Clinical research1.2-1.56xQ3 2026 book-to-bill at IQVIA and ICON: demand is backOpen →Contract manufacturing+11-20%2026 growth guidance at Lonza and Samsung Biologics: capacity is tightOpen →APIs74%China's share of India's API imports, FY25Open →Lab supplies+5-6%Organic growth at Thermo Fisher and Avantor in Q3 2026: demand recoveringOpen →
Across R&D
Exhibit 1Supplier growth across R&D
Latest quarter, year on year
OfficialIQVIA Q3 2026 results (8-K) · Oct-Nov 2026
Market pulse
4 Nov 2026
Charles River organic +4.7%
Preclinical demand above 1x for a fourth quarter.
Charles River Q3 2026 results (8-K) →28 Oct 2026
Avantor returns to growth
Distribution margins down; buyers' market.
Avantor (SEC) →27 Oct 2026
IQVIA best clinical bookings since 2022
$3.2bn, +15%.
IQVIA Q3 2026 results (8-K) →26 Oct 2026
WuXi AppTec raises guide ahead of BIOSECURE list
List due 18 Dec.
Fierce Pharma →29 Sep 2026
US patented drug tariffs apply to all importers
100% default; generics exempt for now.
GHY →Sources
- IQVIA Q3 2026 results (8-K) · Oct 2026
- Lonza Q3 2026 · Oct 2026
- Section 232 (JD Supra) · Apr 2026
- Ministry of Chemicals and Fertilizers (reply to Parliament, Mar 2026) · Sep 2026
- Thermo Fisher Q3 2026 results and call · Oct 2026